November 2022 - Page 4 of 4 - BioMedWire (BMW)

MondayNov 07, 2022 10:32 am

New Brain Cancer Clinical Trial Platform Launched in Australia

Over the last 30 years, the five-year survival rate of patients with brain cancer in Australia hasn’t changed, remaining at about 22%. Now, researchers are planning to launch a clinical trial platform that will revolutionize studies on new treatments for brain cancer and help deliver more personalized and targeted therapies for patients not just in Australia but around the world. The platform, titled the Brain-POP (brain perioperative), will allow physicians to observe the effect of a new drug treatment on a brain-cancer patient by comparing samples of tumors obtained prior to and following therapy administration. The platform will be the…

MondayNov 07, 2022 10:30 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Is ‘One to Watch’

BiondVax has an exclusive worldwide license to commercialize NanoAbs for the treatment of COVID-19 The company plans to initiate a Phase 1/2a clinical trial of its inhaled COVID-19 therapeutic NanoAb in 2023 BiondVax has exclusive options for worldwide licenses for NanoAbs to treat other disorders with large, underserved needs The company has filed a Registration Statement with the SEC for an underwritten offering of shares BiondVax Pharmaceuticals (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. In collaboration with the prestigious Max Planck Institute…

MondayNov 07, 2022 9:45 am

New Pharmaceutical Subsidiary Geared to Aid Odyssey Health, Inc. (ODYY) Development of Novel Solutions for Brain Related Medical Treatments

Odyssey Health Inc. is a medical product developer with a mission of filling unmet needs when it comes to acute emergencies involving patients’ central nervous systems The company recently announced the formation of a wholly owned subsidiary to help Odyssey develop its products as they move through the regulatory process Odyssey’s solutions include a breath-powered intranasal delivery mechanism and synthetic neurosteroids designed to provide rapid-response treatment for patients with concussions and a highly fatal pediatric neurological disease Odyssey Health also is developing solutions for heart disease detection, obstructed-airway choking and nerve agent exposure The concussion therapeutic solution recently completed Phase…

FridayNov 04, 2022 11:26 am

Experts Concerned That Concussion Protocols Don’t Factor in Women

Since the early 2000s, research on concussions has improved significantly. Concussions are traumatic brain injuries that affect the brain function of an individual. It is estimated that millions of Americans experience concussions annually, with a survey conducted by the CDC in 2017 finding that 2.5 million students in high school had experienced concussions in 2016. Of this figure, which represents about 15% of all students in high school in the country, at least 40% of those who experienced concussions were girls. While increasing awareness among the American public may have led to the greater numbers of teens reporting concussions, not…

FridayNov 04, 2022 9:45 am

Silo Pharma Inc. (NASDAQ: SILO) Extends Columbia University Agreement to Continue Research for Therapeutics to Treat Alzheimer’s Disease

Silo recently extended Columbia University agreement to continue research for novel therapeutics to treat Alzheimer’s disease and stress-induced anxiety disorder Preclinical studies demonstrate Silo’s jointly-developed Z-pod(TM) delivery technology holds and distributes therapeutics in a time-released manner to potentially provide targeted delivery Additional treatment research includes funding for the UCSF Translational Psychedelic Program to study effects of psilocybin on various inflammatory conditions Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company, fuses traditional therapeutics with psychedelic medicine to treat numerous underserved conditions, including fibromyalgia, post-traumatic stress disorder, and Alzheimer’s disease. Through a joint partnership agreement with Columbia University, researchers are currently…

ThursdayNov 03, 2022 1:43 pm

Research Finds That Stem Cells Reduce Lung Transplant Rejection Rates

Organ rejection usually occurs when the immune system of the recipient of a transplanted organ treats the transplanted organ as a foreign object and attacks it. At the moment, patients can only reduce the risk of organ rejection by taking immunosuppressants, which alleviate symptoms of rejection but make patients more susceptible to infections. It is estimated that over one-half of patients who receive donor lungs experience organ rejection. Researchers believe that frequent rejection rates and continuous exposure to bacteria and particulates in the air cause irritation while also stimulating the immune system to attack the donor lungs. While medical advancements…

WednesdayNov 02, 2022 1:01 pm

Study Finds Covid-19 Spikes Linked to Increases in Heart Attacks

More than two years after the novel coronavirus was first discovered in Wuhan, China, the infectious virus is still wreaking havoc among the global population. Although most countries, with the notable exception of China, have almost wholly loosened their tight pandemic policies, the respiratory disease is still taking lives every day. By mid-September 2022, hundreds of Americans were still losing their lives to COVID, with Centers for Disease Control and Prevention’s director, Dr. Rochelle Walensky, stating that the country was losing up to 375 patients per day due to the virus. Data from the Cedars Sinai Smidt Heart Institute has…

WednesdayNov 02, 2022 9:45 am

India Globalization Capital Inc. (NYSE American: IGC) Is ‘One to Watch’

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC based formulation on Alzheimer’s patients The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. India Globalization Capital (NYSE American: IGC), through subsidiary…

TuesdayNov 01, 2022 11:29 am

Study Finds Epigenetics May Revolutionize Treatment of Cancer

A new study has led to the discovery of new information about the role of epigenetics in cancer development. Epigenetics refers to the study of how an individual’s environment and behaviors cause changes that affect the way their genes work. The study, which was conducted by scientists at the Institute of Cancer Research in London, suggests that dark matter may change the detection and treatment of cancer. It may also facilitate the development of new tests for this illness, which will be useful in tailoring therapies. Prior studies have primarily focused on how structural changes to individual DNA, which cause…